Uptake of biosimilars in China: a retrospective analysis of the case of trastuzumab from 2018 to 2023
Abstract Background The Chinese biosimilar industry has demonstrated rapid growth in recent years. Limited evidence is available about biosimilar uptake at the national level. This study aimed to assess biosimilar uptake in the case of trastuzumab and to explore potential factors influencing the bio...
I tiakina i:
| Ngā kaituhi matua: | , , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
KeAi Communications Co., Ltd.
2024-10-01
|
| Rangatū: | Global Health Research and Policy |
| Ngā marau: | |
| Urunga tuihono: | https://doi.org/10.1186/s41256-024-00372-z |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|